Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy

[1]  J. C. Christiansen,et al.  Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. , 2020, Annals of internal medicine.

[2]  A. Feldman,et al.  Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. , 2000, The Journal of clinical investigation.

[3]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[4]  M. Kotlikoff,et al.  Calcium-induced calcium release in smooth muscle: loose coupling between the action potential and calcium release. , 2000 .

[5]  C. Hayward,et al.  The roles of gender, the menopause and hormone replacement on cardiovascular function. , 2000, Cardiovascular research.

[6]  J. V. Falvo,et al.  Stimulus-Specific Assembly of Enhancer Complexes on the Tumor Necrosis Factor Alpha Gene Promoter , 2000, Molecular and Cellular Biology.

[7]  S. Fleischer,et al.  Three Amino Acid Residues Determine Selective Binding of FK506-binding Protein 12.6 to the Cardiac Ryanodine Receptor* , 1999, The Journal of Biological Chemistry.

[8]  W. Lim,et al.  Effect of hormone replacement therapy on left ventricular hypertrophy. , 1999, The American journal of cardiology.

[9]  M. Corretti,et al.  Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. , 1999, Circulation Research.

[10]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[11]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[12]  M. Matzuk,et al.  Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12 , 1998, Nature.

[13]  M. Kotlikoff,et al.  Inactivation of calcium-activated chloride channels in smooth muscle by calcium/calmodulin-dependent protein kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J Sandelski,et al.  Evaluation of ventricular and arterial hemodynamics in anesthetized closed-chest mice. , 1997, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  W. Lederer,et al.  Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. , 1997, Science.

[16]  S. Fleischer,et al.  Different interactions of cardiac and skeletal muscle ryanodine receptors with FK-506 binding protein isoforms. , 1997, The American journal of physiology.

[17]  S. Fleischer,et al.  Selective Binding of FKBP12.6 by the Cardiac Ryanodine Receptor* , 1996, The Journal of Biological Chemistry.

[18]  A. Marks.  Cellular functions of immunophilins. , 1996, Physiological reviews.

[19]  E. A. O'neill,et al.  A Novel FK506 Binding Protein Can Mediate the Immunosuppressive Effects of FK506 and Is Associated with the Cardiac Ryanodine Receptor (*) , 1995, The Journal of Biological Chemistry.

[20]  A. P. Timerman,et al.  Characterization of an Exchange Reaction between Soluble FKBP-12 and the FKBP·Ryanodine Receptor Complex , 1995, The Journal of Biological Chemistry.

[21]  A. Marks,et al.  Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein , 1994, Cell.

[22]  A. Marks,et al.  The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. , 1993, The Journal of biological chemistry.

[23]  M. Murcko,et al.  Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. , 1992, The Journal of biological chemistry.

[24]  H. Erdjument-Bromage,et al.  FK506 binding protein associated with the calcium release channel (ryanodine receptor). , 1992, The Journal of biological chemistry.

[25]  R. Bronson,et al.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene , 1991, Cell.

[26]  R F Standaert,et al.  Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex , 1991, Science.

[27]  L. Neyses,et al.  Modulation of cardiac hypertrophy by estrogens. , 1997, Advances in experimental medicine and biology.

[28]  G. Meissner,et al.  Ryanodine receptor/Ca2+ release channels and their regulation by endogenous effectors. , 1994, Annual review of physiology.

[29]  S. Fleischer,et al.  Biochemistry and biophysics of excitation-contraction coupling. , 1989, Annual review of biophysics and biophysical chemistry.